Elizabeth Blasiak on the Hourly Rounding Program Results

Patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer derived benefit with adjuvant osimertinib.

For this episode of “The Vitals,” Aliènne Salleroli, MS, BSN, RN, OCN, discusses her research on equity, diversity, and inclusion in oncology nurse leadership.

An observational study of 2450 patients with stage III colon cancer identified key factors that may increase a patient’s risk of oxaliplatin-induced peripheral neuropathy.

In this episode of “The Vitals,” 2 veteran oncology nurses discuss the value of mentorship—particularly for novice nurses.

"Over the last decade, the landscape of systemic anti-cancer therapy has changed dramatically following the approvals of multiple new targeted therapies," - Kerin Adelson, MD.

Pilot programs based out of Yale Cancer Center and Moffitt Cancer Center seek to improve access for newly diagnosed patients with cancer.